Share

July 23, 2013; 81 (4) Article

Life-span cognitive activity, neuropathologic burden, and cognitive aging

Robert S. Wilson, Patricia A. Boyle, Lei Yu, Lisa L. Barnes, Julie A. Schneider, David A. Bennett
First published July 3, 2013, DOI: https://doi.org/10.1212/WNL.0b013e31829c5e8a
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2023

Share

Article Information

vol. 81 no. 4 314-321
DOI: 
https://doi.org/10.1212/WNL.0b013e31829c5e8a
PubMed: 
23825173
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received January 9, 2013
  • Accepted in final form March 14, 2013
  • First Published July 3, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Robert S. Wilson, PhD,
    2. Patricia A. Boyle, PhD,
    3. Lei Yu, PhD,
    4. Lisa L. Barnes, PhD,
    5. Julie A. Schneider, MD and
    6. David A. Bennett, MD
  1. Robert S. Wilson, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Aging, Neuropsychology, and Cognition, Consulting Editor, 2004-present; (2) Psychology and Aging, Consulting Editor, 2007-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Pain Therapeutics, Inc.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH/NIA R01AG024871, PI, 2006-2011; (2) NIH/NIA P30AG10161, Co-I, 1991-2011; (3) NIH/NIA R01AG11101, Co-I, 1993-2011; (4) NIH/NIA R01AG15819, Co-I, 1998-2013

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Patricia A. Boyle, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH/NIA R01AG034374, PI; (2) NIH/NIA R01AG033678, PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Lei Yu, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH R01AG033678 [co-investigator], NIH R01AG024871 [co-investigator], NIH R01AG024871 [co-investigator], NIH P30AG010161 [co-investigator], NIH R01AG015819 [co-investigator], NIH R01HL096944 [co-investigator], NIH R01AG036042 [co-investigator], NIH R01AG038651 [co-investigator], NIH R01AG040039 [co-investigator], NIH R01AG034374 [co-investigator], NIH U01AG032984 [co-investigator]

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Lisa L. Barnes, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Aging And Health, member of editorial board, 2006 - present. No compensation received.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultant on NIH R13AG044140

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Julie A. Schneider, MD and
    6. Scientific Advisory Boards:

    1. 1. served on scientific advisory board for GE Healthcare (2010) 2. served on scientific advisory board for Eli Lilly and Company (2011)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 2005-current Journal Histochemistry and Cytochemistry (Monitoring editor) 2008-current International Journal of Clinical and Experimental Pathology (IJCEP, ISSN 1936-2625) (Editorial Board) 2010 Journal of Alzheimer's Disease (Associate Editor)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Neuropathology consultant, AVID radiopharmaceuticals 2009-12

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. AVID radiopharmaceutical phase III clinical trial Neuropathologist 2010-2011

    Research Support, Government Entities:

    1. 1R01AG042210 (Schneider) 07/1/12- 06/30/17 Epidemiologic Study of TDP-43 Pathology in Aging and Dementia Major goal is to determine whether age-related TDP-43 pathology represents a separate pathologic process associated with a dementia syndrome with a distinct cognitive phenotype and specific genetic risk factors that are separate from AD. Role: Principal investigator R01NS078009 (Buchman) 9/15/12-6/30/17 NINDS The Clinical Profile of Parkinson's Disease (PD) Pathology. The overall goal is to characterize the clinical profile of PD pathology in older persons without a diagnosis of PD. Role: co-investigator R01AG043379 (Buchman) 9/30/12-8/31/17 NIA Brain and Spinal Cord Microvascular Pathology in Late-Life Motor Impairment The overall goal is to test the hypothesis that specific microvascular pathologies in the brain and spinal cord contribute to late-life motor impairment. U01AG016976 (Kukull/Montine) 7/1/12-6/30/13 NIA (Pilot) Optimization of Neuropathologic Assessment of Alzheimer's Disease; The overall goal is to optimize neuropathologic diagnosis of Alzheimer's disease for uniformity and accurancy across centers Role: Site Principal Investigator P30 AG10161 (Bennett) 9/30/91-6/30/16 Rush Alzheimer's Disease Core Center Major goals to provide core infrastructure support for research regarding aging/dementia/AD. Role: Associate Director, Core Leader: Neuropathology Core R01 AG031553 (Morris) 3/15/08 - 2/28/13 Epidemiologic Study of Brain Vitamin E, Diet, and Age-Related Neurologic Diseases; Major goal is analyze Vitamin E in brain, CSF, serum, and diet and compare to neuropathology and dementia. Role: Co-Principal Investigator R01 AG17917 (Bennett) 9/30/01-6/30/13 Epidemiologic Study of Neural Reserve and Neurobiology of Aging; Major goals are to identify structural bases of reserve and examine mechanisms risk factors lead to age-related functional impairment. Role: Co-Investigator R01 AG15819 (7/1/98 - 6/30/13 Risk Factors, Pathology and Clinical Expressions of AD The major goals of this project are to examine the pathologic mechanisms through which risk factors lead to clinical AD. Role: Co-investigator P01 AG14449 (Mufson) 9/1/97 - 3/31/13 Neurobiology of Mild cognitive impairment in the Elderly; The major goals are to identify neurobiologic substrates of mild cognitive impairment. Role: Co-investigator (Neuropathologist) R01AG033678-01 (Boyle) 9/15/2009 - 6/30/14 Epidemiologic study of impaired decision making in preclinical Alzheimer's disease. The overall goal of the proposed epidemiologic study is to examine the causes and consequences of impaired decision-making in old age. Role: Neuropathologist R01AG034374 (Boyle) 8/15/2009 -7/31/14 Characterizing the behavior profile of healthy cognitive aging. Goal is to use innovative statistical approaches to characterize the profile of healthy cognitive aging defined as age-related cognitive change not accounted for by the presence of common neuropathologies (i.e., Alzheimer's disease, cerebral infarcts, and the Lewy body diseases) or terminal decline. Role: Neuropathologist. P01 AG09466 (deToledo-Morrell) 4/1/1991-8/31/12 Anatomic, Physiologic, Cognitive Pathology of AD; major goals- to identify neurobiologic, radiologic, physiologic, cognitive markers with AD; Role: Co-Investigator; Neuropathologist, Administrative Core R01 AG36042 (Bennett) 9/15/09-8/31/14 Exploring the Role of the Brain Epigenome: Cognitive Decline and Life Experiences The goal of the study is to examine the relation of DNA methylation to cognitive decline and life experiences. Role: Neuropathologist R01 HL096944 (Levine) 9/1/09 - 6/30/13 Stroke and aPL: Community-Based Clinicopathologic Study The major goal of this project is to investigate the role and mechanisms of antiphospholipid antibodies (aPL) in the development of pathologically-proven ischemic brain infarction. Role: Neuropathologist R01AG040039 (Arvanitakis) 9/30/11-8/31/16 National Institute on Aging Vascular Cognitive and Motor Decline: Impact of aPL The major goal of this project is to investigate the role and mechanisms of antiphospholipid antibodies (aPL) in the development of cognitive and motor decline in aging. R01AG039478 (Arnold) 4/1/11-3/31/16 National Institute on Aging Targeted Proteomics of Resilient Cognition in Aging The major goal of the study is to identify candidate proteins and pathways that best confer cognitive resilience despite the accumulation of neurodegenerative disease pathology. Role: Neuropathologist R01AG036836 (DeJager) 9/15/11-8/31/15 National Institute on Aging Exploring the Role of the Brain Transcriptome in Cognitive Decline The major goal is to investigate the transcriptome of human brain tissue to identify molecular pathways that contribute to cognitive decline. Role: Neuropathologist

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. David A. Bennett, MD
    7. Scientific Advisory Boards:

    1. (1) Vigorous Minds, Scientific Advisory Board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Danone, paid for travel to scientific meeting

    Editorial Boards:

    1. (1) Neurology, Editorial Board; (2) Current Alzheimer Research, Editorial Board; (3) Neuroepidemiology, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Danone, Inc., (2) Wilmar Schwabe GmbH & Co., (3) Eli Lilly, Inc., (4) the Gerson Lehrman Group, (5) Enzymotec Ltd.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Danone Inc., PI

    Research Support, Government Entities:

    1. NIH: P30AG10161, PI; R01AG15819, PI; R01AG17917, PI; R01AG36042, PI; U01AG32984, Co-I; R01AG22018, Co-I; R01AG33678, Co-I; R01AG36836, Co-I; R01AG41797, Co-I; R01AG42210, Co-I; and Illinois Department Public Health

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Rush Alzheimer's Disease Center and Departments of Neurological Sciences (R.S.W., L.Y., L.L.B., J.A.S., D.A.B.), Behavioral Sciences (R.S.W., P.A.B., L.L.B.), and Pathology (J.A.S.), Rush University Medical Center, Chicago, IL.
  1. Correspondence to Dr. Wilson: rwilson{at}rush.edu
View Full Text

Article usage

Article usage: July 2013 to April 2023

AbstractFullPdfSource
Jul 20131157239267Highwire
Aug 201319322050Highwire
Sep 201312402041Highwire
Oct 201312292351Highwire
Nov 201311181228Highwire
Dec 201384628Highwire
Jan 2014826916Highwire
Feb 20141041817Highwire
Mar 201484364Highwire
Apr 2014958310Highwire
May 201459665Highwire
Jun 201456725Highwire
Jul 201472224Highwire
Aug 201439721Highwire
Sep 201472824Highwire
Oct 20141125108Highwire
Nov 201479936Highwire
Dec 201473924Highwire
Jan 2015107467Highwire
Jan 20150618pmc
Feb 201597626Highwire
Feb 201505615pmc
Mar 201575413Highwire
Mar 201504926pmc
Apr 2015111848Highwire
Apr 201504421pmc
May 2015760510Highwire
May 20150367pmc
Jun 201595413Highwire
Jun 201504012pmc
Jul 201558917Highwire
Jul 201506720pmc
Aug 2015136902Highwire
Aug 201504313pmc
Sep 2015145331Highwire
Sep 201503620pmc
Oct 2015112554Highwire
Oct 20150296pmc
Nov 2015149021Highwire
Nov 201503717pmc
Dec 2015129223Highwire
Dec 201504312pmc
Jan 2016123121Highwire
Jan 201604412pmc
Feb 2016115822Highwire
Feb 20160799pmc
Mar 2016138713Highwire
Mar 201605418pmc
Apr 2016163015Highwire
Apr 201604418pmc
May 2016141963Highwire
May 20160379pmc
Jun 2016107622Highwire
Jun 201604513pmc
Jul 2016113200Highwire
Jul 201604113pmc
Aug 2016139802Highwire
Aug 201604710pmc
Sep 2016164944Highwire
Sep 20160658pmc
Oct 2016168042Highwire
Oct 201605918pmc
Nov 2016193500Highwire
Nov 201608210pmc
Dec 2016127841Highwire
Dec 201605110pmc
Jan 2017147510Highwire
Jan 20170459pmc
Feb 2017130213Highwire
Feb 201706113pmc
Mar 2017155400Highwire
Mar 201708023pmc
Apr 2017254721Highwire
Apr 201719103113pmc
May 2017184112Highwire
May 201711102125pmc
Jun 201790012Highwire
Jun 2017137792pmc
Jul 201789728Highwire
Jul 201774556pmc
Aug 2017102711Highwire
Aug 2017225859pmc
Sep 2017125810Highwire
Sep 2017137082pmc
Oct 2017139524Highwire
Oct 2017167791pmc
Nov 2017141576Highwire
Nov 2017125970pmc
Dec 2017116572Highwire
Jan 2018122640Highwire
Feb 20181133162Highwire
Mar 2018140585Highwire
Apr 2018139282Highwire
Apr 2018146582pmc
May 2018136201Highwire
Jun 2018105931Highwire
Jun 201844053pmc
Jul 20181275105Highwire
Aug 2018104911Highwire
Aug 2018104954pmc
Sep 2018162096Highwire
Oct 2018182832Highwire
Nov 2018196769Highwire
Dec 2018214611Highwire
Jan 2019206125Highwire
Feb 2019166561Highwire
Mar 2019155080Highwire
Apr 2019153781Highwire
May 2019127421Highwire
Jun 2019108330Highwire
Jul 20191065101Highwire
Aug 201996575Highwire
Sep 2019121861Highwire
Oct 2019164653Highwire
Nov 20191598123Highwire
Dec 2019174432Highwire
Jan 2020134042Highwire
Feb 2020138041Highwire
Mar 2020149422Highwire
Apr 2020179732Highwire
May 2020186241Highwire
Jun 2020135830Highwire
Jul 2020118266Highwire
Aug 2020113910Highwire
Sep 2020164584Highwire
Oct 2020191231Highwire
Nov 2020240062Highwire
Dec 2020168310Highwire
Jan 2021158561Highwire
Feb 2021154682Highwire
Mar 2021166190Highwire
Apr 20211878155Highwire
May 20211965100Highwire
Jun 2021211472Highwire
Jul 2021154771Highwire
Aug 2021204070Highwire
Sep 2021201372Highwire
Oct 2021192665Highwire
Nov 2021206467Highwire
Dec 2021170382Highwire
Jan 2022171921Highwire
Feb 2022165831Highwire
Mar 2022198653Highwire
Apr 20221676120Highwire
May 20221395105Highwire
Jun 2022113130Highwire
Jul 2022138543Highwire
Aug 2022161833Highwire
Sep 2022164352Highwire
Oct 2022193991Highwire
Nov 2022244493Highwire
Dec 2022152841Highwire
Jan 2023153951Highwire
Feb 2023187094Highwire
Mar 20231857133Highwire
Apr 20231492101Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles